We found that loss of Smad4 immunolabeling was associated with female patients (p = 0.015), patients with serum levels of CA19-9 > 37 U/mL (p = 0.003), patients with tumors in the body and tail of pancreas (p < 0.001), patients with a tumor size >2 cm (p = 0.028), and patients grouped into the T category of UICC classification (p = 0.040). Here, SMAD4 is linked to neoplasm.